Advertisement
Table 1 Characteristics of the 511 diffuse large B-cell lymphoma (DLBCL) patients in the entire cohort and the central nervous system (CNS) relapse cohort (CHOP vs. R-CHOP)
| Clinical factor | Entire cohort [cases (%)] | CNS relapse cohort [cases (%)] | ||||
|---|---|---|---|---|---|---|
| CHOP | R-CHOP | P | CHOP | R-CHOP | P | |
| Total | 135 | 376 | 11 | 14 | ||
| Age | 0.563 | 1.000 | ||||
| ≤60 years | 98 (72.6) | 263 (69.9) | 8 (72.7) | 10 (71.4) | ||
| >60 years | 37 (27.4) | 113 (30.1) | 3 (27.3) | 4 (28.6) | ||
| Gender | 0.694 | 0.115 | ||||
| Male | 76 (56.3) | 219 (58.2) | 5 (45.5) | 11 (78.6) | ||
| Female | 59 (43.7) | 157 (41.8) | 6 (54.5) | 3 (21.4) | ||
| Stage | 0.892 | 0.434 | ||||
| I or II | 77 (57.0) | 217 (57.7) | 5 (45.5) | 4 (28.6) | ||
| III or IV | 58 (43.0) | 159 (42.3) | 6 (54.5) | 10 (71.4) | ||
| B symptoms | 0.663 | 1.000 | ||||
| No | 95 (70.4) | 272 (72.3) | 7 (63.6) | 8 (57.1) | ||
| Yes | 40 (29.6) | 104 (27.7) | 4 (36.4) | 6 (42.9) | ||
| Bulky diseasea,b | 0.238 | 0.500 | ||||
| No | 91 (67.4) | 252 (67.0) | 6 (54.5) | 8 (57.1) | ||
| Yes | 10 (7.4) | 17 (4.5) | 0 (0) | 2 (14.3) | ||
| Involved extranodal sitesc | 0.617 | 0.414 | ||||
| ≤1 | 112 (83.0) | 303 (80.6) | 8 (72.7) | 7 (50) | ||
| >1 | 23 (17.0) | 71 (18.9) | 3 (27.3) | 7 (50) | ||
| Sinus involvement | 0.971 | 0.604 | ||||
| No | 119 (88.1) | 331 (88.0) | 10 (90.9) | 11 (78.6) | ||
| Yes | 16 (11.9) | 45 (12.0) | 1 (9.1) | 3 (21.4) | ||
| Bone involvement | 0.947 | 0.407 | ||||
| No | 120 (88.9) | 335 (89.1) | 9 (81.8) | 9 (64.3) | ||
| Yes | 15 (11.1) | 41 (10.9) | 2 (18.2) | 5 (35.7) | ||
| Bone marrow involvement | 0.177 | 0.230 | ||||
| No | 133 (98.5) | 360 (95.7) | 11 (100) | 11 (78.6) | ||
| Yes | 2 (1.5) | 16 (4.3) | 0 (0) | 3 (21.4) | ||
| Liver involvement | 0.792 | 0.487 | ||||
| No | 131 (97.0) | 361 (96.0) | 11 (100) | 12 (85.7) | ||
| Yes | 4 (3.0) | 15 (4.0) | 0 (0) | 2 (14.3) | ||
| Testicular involvement | 0.526 | 1.000 | ||||
| No | 131 (97.0) | 368 (97.9) | 11 (100) | 13 (92.9) | ||
| Yes | 4 (3.0) | 8 (2.1) | 0 (0) | 1 (7.1) | ||
| Renal involvement | 0.782 | 0.661 | ||||
| No | 130 (96.3) | 360 (95.7) | 9 (81.8) | 10 (71.4) | ||
| Yes | 5 (3.7) | 16 (4.3) | 2 (18.2) | 4 (28.6) | ||
| Breast involvement | 0.318 | – | ||||
| No | 130 (96.3) | 368 (97.9) | 11 (100) | 14 (100) | ||
| Yes | 5 (3.7) | 8 (2.1) | 0 (0) | 0 (0) | ||
| Female genital tract involvement | 0.063 | – | ||||
| No | 131 (97.0) | 373 (99.2) | 11 (100) | 14 (100) | ||
| Yes | 4 (3.0) | 3 (0.8) | 0 (0) | 0 (0) | ||
| IPI | 0.096 | 0.208 | ||||
| 0–2 | 113 (83.7) | 289 (76.9) | 9 (81.8) | 7 (50.0) | ||
| 3–5 | 22 (16.3) | 87 (23.1) | 2 (18.2) | 7 (50.0) | ||
| LDHd | 0.768 | 0.677 | ||||
| ≤1 ULNe | 79 (58.5) | 215 (57.2) | 3 (27.3) | 6 (42.9) | ||
| >1 ULN | 55 (40.7) | 159 (42.3) | 8 (72.7) | 8 (57.1) | ||
| ALB | 0.464 | 0.656 | ||||
| <35 g/L | 114 (84.4) | 327 (87.0) | 4 (36.4) | 3 (21.4) | ||
| ≥35 g/L | 21 (15.6) | 49 (13.0) | 7 (63.6) | 11 (78.6) | ||
| ALPf | 0.529 | 1.000 | ||||
| ≤110 U/L | 119 (88.1) | 341 (90.7) | 8 (72.7) | 10 (71.4) | ||
| >110 U/L | 15 (11.1) | 35 (9.3) | 3 (27.3) | 4 (28.6) | ||
| IT chemotherapy prophylaxisg | 0.640 | 0.661 | ||||
| No | 117 (86.7) | 329 (87.5) | 9 (81.8) | 10 (71.4) | ||
| Yes | 18 (13.3) | 44 (11.7) | 2 (18.2) | 4 (28.6) | ||
| TTCh | 0.016 | 0.003 | ||||
| ≤108 days | 54 (40.0) | 207 (55.1) | 0 (0) | 7 (50.0) | ||
| >108 days | 67 (49.6) | 155 (41.2) | 10 (90.9) | 3 (21.4) | ||
